H
Huug Obertop
Researcher at University of Amsterdam
Publications - 170
Citations - 14371
Huug Obertop is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Esophagus & Carcinoma. The author has an hindex of 56, co-authored 170 publications receiving 13777 citations.
Papers
More filters
Journal ArticleDOI
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.
Jan B F Hulscher,Johanna W. van Sandick,Angela G. E. M. de Boer,Bas P. L. Wijnhoven,Jan G.P. Tijssen,Paul Fockens,Peep F. M. Stalmeier,Fiebo J.W. ten Kate,Herman van Dekken,Huug Obertop,Hugo W. Tilanus,J. Jan B. van Lanschot +11 more
TL;DR: Although median overall, disease-free, and quality-adjusted survival did not differ statistically between the groups, there was a trend toward improved long-term survival at five years with the extended transthoracic approach.
Journal ArticleDOI
Extended Lymph-Node Dissection for Gastric Cancer
J J Bonenkamp,John J. Hermans,M. Sasako,C.J.H. van de Velde,K. Welvaart,I. Songun,S. Meyer,JThM Plukker,P. van Elk,Huug Obertop,D. J. Gouma,J. J. B. van Lanschot,C.W. Taat,P. W. de Graaf,M.F. von Meyenfeldt,H. W. Tilanus +15 more
TL;DR: The results in Dutch patients do not support the routine use of D2 lymph-node dissection in patients with gastric cancer, as recommended by the Japanese medical community.
Journal ArticleDOI
Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients
J. J. Bonenkamp,I. Songun,K. Welvaart,C.J.H. van de Velde,Jo Hermans,M. Sasako,JThM Plukker,P. van Elk,Huug Obertop,Dirk J. Gouma,C.W. Taat,J. J. B. van Lanschot,S. Meyer,P. W. de Graaf,M.F. von Meyenfeldt,H. W. Tilanus +15 more
TL;DR: Morbidity and mortality differences persisted in almost all subgroup analyses, and D2 dissection should not be used as standard treatment for western patients.
Journal ArticleDOI
Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial
Henk H. Hartgrink,C.J.H. van de Velde,Hein Putter,Johannes J. Bonenkamp,E. Klein Kranenbarg,I. Songun,K. Welvaart,J.H.J.M. van Krieken,Sybren L. Meijer,J. T. Plukker,P. van Elk,Huug Obertop,D. J. Gouma,J. J. B. van Lanschot,C.W. Taat,P. W. de Graaf,M.F. von Meyenfeldt,H. W. Tilanus,M. Sasako +18 more
TL;DR: Overall, extended lymph node dissection as defined in this study generated no long-term survival benefit, and the associated higher postoperative mortality offsets its long- term effect in survival.
Journal ArticleDOI
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.
Jikke M.T. Omloo,Sjoerd M. Lagarde,Jan B F Hulscher,Johannes B. Reitsma,Paul Fockens,Herman van Dekken,Fiebo J.W. ten Kate,Huug Obertop,Hugo W. Tilanus,J. Jan B. van Lanschot +9 more
TL;DR: There is no significant overall survival benefit for either approach, however, compared with limited transhiatal resection extended transthoracic esophagectomy for type I esophageal adenocarcinoma shows an ongoing trend towards better 5-year survival.